# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-02-05
**æ›´æ–°æ—¶é—´**: 2026-02-06 04:14
**æ–°é—»æ•°é‡**: 105

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šå‘ˆç°å¤šç»´åº¦æ´»è·ƒæ€åŠ¿ï¼ŒAIé©±åŠ¨çš„æ–°è¯ç ”å‘å…¬å¸Generate:Biomedicinesåœ¨å¯åŠ¨å…³é”®IIIæœŸè¯•éªŒåè¿…é€Ÿç”³è¯·IPOï¼Œå‡¸æ˜¾äº†èµ„æœ¬å¸‚åœºå¯¹AIåˆ¶è¯çš„é«˜åº¦å…³æ³¨ã€‚åŒæ—¶ï¼Œå›´ç»•GLP-1è¯ç‰©ï¼ˆå¦‚è¯ºå’Œè¯ºå¾·çš„Wegovyï¼‰çš„å¸‚åœºç«äº‰åŠ å‰§ï¼ŒHims & Hersæ¨å‡ºä½ä»·å¤æ–¹ç‰ˆæœ¬å¼•å‘æ³•å¾‹ä¸ç›‘ç®¡äº‰è®®ï¼Œè€Œç¤¼æ¥å’Œè¯ºå’Œè¯ºå¾·å‡­å€Ÿå¼ºåŠ²é”€å”®æ•°æ®ç»§ç»­ä¸»å¯¼è¯¥é¢†åŸŸã€‚æ­¤å¤–ï¼Œç¾å›½æ”¿åºœçš„èµ„é‡‘æ³•æ¡ˆé‡æ–°æˆæƒäº†ç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’ï¼Œä¸ºç›¸å…³è¯ç‰©å¼€å‘æä¾›äº†æ”¿ç­–æ¿€åŠ±ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**1. Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs** â­â­â­â­â­
   - ç±»åˆ«: æ–°è¯ç ”å‘
   - AIåˆ¶è¯é¢†å†›ä¼ä¸šåœ¨å…³é”®IIIæœŸè¯•éªŒå¯åŠ¨åç«‹å³ç”³è¯·IPOï¼Œæ ‡å¿—ç€AIé©±åŠ¨è¯ç‰©ç ”å‘è¿›å…¥èµ„æœ¬åŒ–å…³é”®é˜¶æ®µï¼Œå¯¹è¡Œä¸šå…·æœ‰é£å‘æ ‡æ„ä¹‰ã€‚

**10. Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action** â­â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - GLP-1è¯ç‰©å¸‚åœºç«äº‰ç™½çƒ­åŒ–ï¼Œä½ä»·å¤æ–¹ç‰ˆæœ¬çš„å‡ºç°å¯èƒ½é¢ è¦†å®šä»·æ¨¡å¼ï¼Œå¼•å‘å“ç‰Œè¯ä¼æ³•å¾‹åå‡»ä¸FDAç›‘ç®¡å…³æ³¨ï¼Œå½±å“å·¨å¤§ã€‚

**2. FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill** â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - ç¾å›½æ”¿åºœèµ„é‡‘æ³•æ¡ˆé‡æ–°æˆæƒç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’è‡³2029å¹´ï¼Œä¸ºç›¸å…³è¯ç‰©ç ”å‘æä¾›äº†æŒç»­çš„æ”¿ç­–æ¿€åŠ±ï¼Œå½±å“ç ”å‘å¯¼å‘ã€‚

**14. Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - ç¤¼æ¥å…¬å¸GLP-1è¯ç‰©Mounjaroå’ŒZepboundé”€å”®åŠ¿å¤´å¼ºåŠ²ï¼Œ2025å¹´åˆè®¡é”€å”®é¢è¶…360äº¿ç¾å…ƒï¼Œå…¶2026å¹´ä¹è§‚é¢„æµ‹å·©å›ºäº†å…¶åœ¨ä»£è°¢ç–¾ç—…é¢†åŸŸçš„é¢†å¯¼åœ°ä½ã€‚

**17. Amgen resists FDA request to pull rare disease drug Tavneos from the market** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - å®‰è¿›å…¬å¸ç½•è§ç—…è¯ç‰©Tavneosé¢ä¸´FDAæ’¤å¸‚è¦æ±‚ä½†äºˆä»¥æ‹’ç»ï¼Œå‡¸æ˜¾äº†è¯å“ä¸Šå¸‚åç›‘ç®¡ä¸è¯ä¼ä¹‹é—´çš„æ½œåœ¨å†²çªï¼Œå¯¹ç½•è§ç—…è¯ç‰©å¸‚åœºæœ‰è­¦ç¤ºä½œç”¨ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): ä»¥Generate:Biomedicinesä¸ºä»£è¡¨çš„AIé©±åŠ¨è¯ç‰©å‘ç°å…¬å¸æˆä¸ºç„¦ç‚¹ï¼Œå…¶IPOç”³è¯·ä¸ç ”å‘è¿›å±•åŒæ­¥ï¼Œæ˜¾ç¤ºæŠ€æœ¯å¹³å°æ­£åŠ é€Ÿå‘ä¸´åºŠå’Œèµ„æœ¬å¸‚åœºè½¬åŒ–ã€‚æ­¤å¤–ï¼ŒVeradermicsé’ˆå¯¹ç”Ÿå‘ç­‰ç¾å­¦é¢†åŸŸçš„å£æœè¯ç‰©ç ”å‘ä¹Ÿè·å¾—èµ„æœ¬é’çã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): æ–°é—»ä¸­ç›´æ¥æåŠçš„ä¸´åºŠè¯•éªŒè¿›å±•è¾ƒå°‘ï¼Œä½†Generate:Biomedicinesåœ¨é¦–ä¸ªæ‚£è€…ç»™è¯9å¤©åå³ç”³è¯·IPOï¼Œæš—ç¤ºå…¶IIIæœŸè¯•éªŒçš„å¯åŠ¨æ˜¯å…³é”®çš„å‚¬åŒ–å‰‚ã€‚BMSä¹Ÿé¢„å‘Šäº†å¤šé¡¹å³å°†åˆ°æ¥çš„åæœŸç®¡çº¿æ•°æ®è¯»å‡ºï¼Œå¯èƒ½å¸¦æ¥æ–°çš„å‚¬åŒ–å‰‚ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

éœ€å¯†åˆ‡å…³æ³¨FDAå¯¹Hims & Hersé”€å”®å¤æ–¹GLP-1è¯ç‰©å¯èƒ½é‡‡å–çš„ç›‘ç®¡è¡ŒåŠ¨ï¼Œä»¥åŠè¯ºå’Œè¯ºå¾·æ˜¯å¦ä¼šæ­£å¼å¯åŠ¨æ³•å¾‹è¯‰è®¼ã€‚åŒæ—¶ï¼ŒGenerate:Biomedicinesç­‰å¤šå®¶ç”Ÿç‰©æŠ€æœ¯å…¬å¸çš„IPOå®šä»·å’Œé¦–æ—¥è¡¨ç°å°†åæ˜ èµ„æœ¬å¸‚åœºå¯¹ç”Ÿç‰©ç§‘æŠ€æ¿å—ï¼Œç‰¹åˆ«æ˜¯AIåˆ¶è¯é¢†åŸŸçš„æƒ…ç»ªã€‚æ­¤å¤–ï¼Œå°åº¦æ”¿åºœå®£å¸ƒçš„11äº¿ç¾å…ƒç”Ÿç‰©åˆ¶å‰‚/ç”Ÿç‰©ç±»ä¼¼è¯æŠ•èµ„è®¡åˆ’çš„å…·ä½“å®æ–½ç»†èŠ‚å€¼å¾—å…³æ³¨ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç»¼åˆ (ç»¼åˆ) | 43 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 12:00
- **é‡è¦æ€§**: â­â­â­â­â­

> Just nine days after dosing the first patient in a Phase 3 trial, Generate:Biomedicines has filed for an IPO. The Flagship Pioneering-backed startup has become a richly-funded leader of AI bio since its founding in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/)

---

### ğŸ‡ºğŸ‡¸ Eikon IPO analysis: Big biotech names, big valuation cut

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 14:32
- **é‡è¦æ€§**: â­â­â­â­

> For Eikon Therapeutics, its IPO feels more like something itâ€™s surviving rather than celebrating. The Bay Area startup is one of biotechâ€™s most prominent privately-held companies, after raising more than $1 billion to advance its ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/)

---

### ğŸ‡ºğŸ‡¸ Rare pediatric PRV program reauthorized until 2029 via government funding law

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 18:27
- **é‡è¦æ€§**: â­â­â­â­

> President Donald Trump on Tuesday signed the government funding extension that also reauthorized the FDA's ability to issue rare pediatric priority reviews through 2029, reviving an incentive program that industry has fought to keep. ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/)

---

### ğŸ‡ºğŸ‡¸ Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 15:22
- **é‡è¦æ€§**: â­â­â­

> Thermo Fisher Scientific is closing its chemical analysis manufacturing site in Franklin, MA, due to â€œcurrent customer demands,â€ a company spokesperson told Endpoints News. Operations there will be phased out by the end of the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/thermo-fisher-charles-river-workforce-cuts-wuxi-signs-contract-with-vertex/)

---

### ğŸ‡ºğŸ‡¸ Agomab, SpyGlass bank a combined $350M in biotech IPOs

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-06 00:59
- **é‡è¦æ€§**: â­â­

> The two offerings capped off the busiest week for new biotech stock issuances in a year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/agomab-spyglass-biotech-ipo-price-2026/811385/)

---

### ğŸ‡ºğŸ‡¸ Novo, Lilly sputter as Hims launches knockoff GLP-1 pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 17:22
- **é‡è¦æ€§**: â­â­

> Novo is threatening litigation in response to the move by the telehealth company to &ldquo;unlawfully mass-market&rdquo; what it called an &ldquo;unapproved, inauthentic, and untested knockoff&rdquo; of its fast-selling medication.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/hims-compounded-wegovy-glp-1-obesity-novo-lilly/811476/)

---

### ğŸ‡ºğŸ‡¸ Generate, an AI-driven Flagship startup, pitches an IPO

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 16:32
- **é‡è¦æ€§**: â­â­

> The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/generate-biomedicines-ipo-flagship-ai-tlsp/811482/)

---

### ğŸ‡ºğŸ‡¸ Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 01:08
- **é‡è¦æ€§**: â­â­

> The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/eikon-biotech-ipo-price-cancer-drugs-2026/811169/)

---

### ğŸ‡ºğŸ‡¸ Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 17:18
- **é‡è¦æ€§**: â­â­

> The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/trump-signs-legislation-end-partial-government-shutdown-pbm-reform-telehealth-hospital-at-home/811365/)

---

### ğŸ‡ºğŸ‡¸ Lilly soars again as fast-selling weight loss drugs top Wall Street projections

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 16:14
- **é‡è¦æ€§**: â­â­

> Despite some angst over pricing pressure for GLP-1 drugs, Lilly&rsquo;s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/lilly-earnings-guidance-q4-2025-obesity-drugs/811317/)

---

### ğŸ‡ºğŸ‡¸ FDA chief Makary takes aim at Hims' compounded Wegovy pill plans

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 23:52
- **é‡è¦æ€§**: â­â­

> FDA Commissioner Marty Makary took a not-so-subtle swipe at Hims &amp; Hers in a social media post Thursday, saying his agency would "take swift action against companies mass-marketing illegal copycat drugs." Without naming Hims, Makary' ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-chief-makary-takes-aim-at-hims-compounded-wegovy-pill-plans/)

---

### ğŸ‡ºğŸ‡¸ Veradermics CEO has a great hair day with 122% pop in IPO

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 18:34
- **é‡è¦æ€§**: â­â­

> Investors are showing some love to the biotech testing an oral form of Rogaine, betting that people will want good hair too as the aesthetics market surges with direct-to-consumer GLP-1s. Veradermics' stock surged 122% in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/veradermics-ceo-has-a-great-hair-day-with-122-pop-in-ipo/)

---

### ğŸ‡ºğŸ‡¸ Bristol Myers draws pipeline excitement as several data readouts near

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 15:50
- **é‡è¦æ€§**: â­â­

> For the first time in a while, investors seem excited about Bristol Myers Squibbâ€™s late-stage pipeline. Bristol Myers on Thursday flagged at least 10 potential data readouts coming this year that could lead to new ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/bristol-myers-draws-pipeline-excitement-as-several-data-readouts-near/)

---

### ğŸ‡ºğŸ‡¸ Telehealth provider Hims goes after Novo's weight loss pill with compounded version

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 14:58
- **é‡è¦æ€§**: â­â­

> Online healthcare provider Hims &amp; Hers said it would start selling a compounded version of Novo Nordiskâ€™s Wegovy pill on Thursday, just a month after the FDAâ€™s approval of the brand-name pill version of the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/telehealth-provider-hims-goes-after-novos-weight-loss-pill-with-compounded-version/)

---

### ğŸ‡ºğŸ‡¸ Eisai gains Henlius therapy; LB Pharma snags $100M in funding

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 14:21
- **é‡è¦æ€§**: â­â­

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eisai-gains-henlius-therapy-lb-pharma-snags-100m-in-funding/)

---

### ğŸ‡ºğŸ‡¸ Veradermics lands $256M IPO for oral Rogaine

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 14:14
- **é‡è¦æ€§**: â­â­

> Veradermics headed out of the gates with an initial public offering that garnered $256 million in gross proceeds, a bigger-than-expected debut that suggests investors may be hungry for a rebound in biotech listings. Veradermics, which ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/)

---

### ğŸ‡ºğŸ‡¸ Hims adds Grail's cancer test amid questions about widespread use

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 14:00
- **é‡è¦æ€§**: â­â­

> Hims &amp; Hers is bringing Grail's cancer test to its consumer health platform, marking a significant step toward mass adoption of a technology that's shown progress while remaining under scientific debate. Grail, a pioneer in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/hims-adds-grails-cancer-test-amid-questions-about-widespread-use/)

---

### ğŸ‡ºğŸ‡¸ Novartis says generics to erode $4B from 2026 sales

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 12:44
- **é‡è¦æ€§**: â­â­

> Novartis said further generic erosion of three blockbuster medicines, including its top-selling heart failure drug Entresto, will leave a $4 billion hole in its sales this year. Generic competition started to make a mark in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/)

---

### ğŸ‡ºğŸ‡¸ FDA seeks withdrawal of Amgen's Tavneos, but company says it won't pull drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 00:48
- **é‡è¦æ€§**: â­â­

> Several years of questions about Amgen's rare disease treatment Tavneos have reached a climax after the FDA asked the company to pull the drug from the market, and Amgen said it has no plans to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-seeks-withdrawal-of-amgens-tavneos-company-says-it-wont-pull-drug/)

---

### ğŸ‡ºğŸ‡¸ Bayer details anticipated stroke prevention data for new blood-thinner

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 17:15
- **é‡è¦æ€§**: â­

> Asundexian&nbsp;cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/bayer-asundexian-factorXIa-secondary-stroke-data-conference/811455/)

---

### ğŸ‡ºğŸ‡¸ #ISC26: Bayerâ€™s asundexian reduced ischemic strokes by 26% in Phase 3 trial

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 17:15
- **é‡è¦æ€§**: â­

> Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/isc26-bayers-asundexian-reduced-ischemic-strokes-by-26-in-phase-3-trial/)

---

### ğŸ‡ºğŸ‡¸ Angitia gets $130M Series D for pipeline of musculoskeletal drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 12:30
- **é‡è¦æ€§**: â­

> A US-China biotech has reeled in $130 million for three biologics in clinical testing for musculoskeletal diseases, including one in which Ultragenyx recently came up short. Angitia Biopharmaceuticals disclosed its Series D ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/)

---

### ğŸ‡ºğŸ‡¸ Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myersâ€™ waiting game

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 21:32

> Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/bristol-myers-abbvie-gsk-vaccines-biotech-earnings-q4-2025/811463/)

---

### ğŸ‡ºğŸ‡¸ Express Scripts reaches â€˜landmarkâ€™ settlement with FTC in insulin suit

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 11:46

> The agreement announced Wednesday includes sweeping changes to the Cigna PBM&rsquo;s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/express-scripts-ftc-reach-settlement-insulin-lawsuit/811436/)

---

### ğŸ‡ºğŸ‡¸ Novo shares tumble by double digits on grim sales outlook

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 16:55

> In contrast to Lilly&rsquo;s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/novo-nordisk-2025-earnings-2026-outlook/811318/)

---

### ğŸ‡ºğŸ‡¸ Novo's threat to sue Hims over Wegovy pill faces legal hurdle

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 21:25

> Novo Nordisk's threatened legal action against Hims &amp; Hers for selling a compounded version of the pharma giantâ€™s newly launched Wegovy pill may be far from a slam-dunk win. Dae Lee, an attorney at Buchanan ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novos-threat-to-sue-hims-over-wegovy-pill-faces-legal-hurdle/)

---

### ğŸ‡ºğŸ‡¸ White House launches TrumpRx

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 20:55

> The White House on Thursday launched TrumpRx, the long-awaited direct-to-consumer hub that's a cornerstone of the administrationâ€™s push to lower drug prices. The official unveiling had been months in the making and was slightly delayed ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/white-house-plans-to-launch-trumprx-thursday/)

---

### ğŸ‡ºğŸ‡¸ GLP-1s and the Super Bowl

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 15:41

> The Super Bowl is once again getting the GLP-1 ad treatment. Hims &amp; Hers is back with another combative spot that calls out the disparities in healthcare experiences between the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/glp-1s-and-the-super-bowl/)

---

### ğŸ‡ºğŸ‡¸ FTC settles insulin lawsuit with Express Scripts

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 20:49

> The FTC has settled with Express Scripts over its use of insulin rebates, securing an agreement that stretches across almost every corner of the company's business model. The commission and Express Scripts

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/ftc-settles-insulin-lawsuit-with-express-scripts/)

---

### ğŸ‡ºğŸ‡¸ AbbVie says immunology blockbusters will be 'main drivers' of growth post-Humira

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 20:40

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/abbvie-says-immunology-blockbusters-will-be-main-drivers-of-growth-post-humira/)

---

### ğŸ‡ºğŸ‡¸ GSKâ€™s new CEO eyes more dealmaking, intense pipeline inspection

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 15:01

> GSK CEO Luke Miels laid out the drugmakerâ€™s vision for how it will meet its 2031 sales forecast and address the upcoming patent cliff for its blockbuster HIV drug dolutegravir. â€œWe need ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/gsks-new-ceo-eyes-more-dealmaking-intense-pipeline-inspection/)

---

### ğŸ‡ºğŸ‡¸ Midi Health raises $100M as it plans expansion into urgent care, research

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 14:00

> Health techâ€™s latest unicorn is Midi Health, a womenâ€™s health startup launched during the pandemic that has since expanded into broader virtual care with a recent focus on longevity. The startup hit ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/midi-health-raises-100m-as-it-plans-expansion-into-urgent-care-research/)

---

### ğŸ‡ºğŸ‡¸ Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 12:10

> Eli Lilly surpassed analysts' expectations for 2025 and fourth-quarter revenues on Wednesday morning, and anticipates a large increase in revenue this year. It marks a sharp juxtaposition to its main rival Novo Nordisk, which expects ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/)

---

### ğŸ‡ºğŸ‡¸ Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 10:55

> Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer's monthly obesity shot. It has also cut a handful of drugs from its pipeline, so it certainly has ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/embattled-novo-nordisk-considers-buying-a-monthly-glp-1-to-bolster-portfolio/)

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 15:02
- **é‡è¦æ€§**: â­â­â­â­

> By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill)

---

### ğŸ‡ºğŸ‡¸ Rising Stars: emagineHealth's Barbara Leal lives and works by the mantra of â€˜humans first, professionals secondâ€™

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 15:25
- **é‡è¦æ€§**: â­â­â­â­

> In a Q&amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Leal explained how healthcare and pharma marketing combines the â€œbest of both worldsâ€ for her.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/rising-stars-barbara-leal-lives-and-works-mantra-humans-first-professionals-second)

---

### ğŸ‡ºğŸ‡¸ Him &amp; Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 12:20
- **é‡è¦æ€§**: â­â­

> A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims &amp; Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/health-tech/him-hers-plans-offer-cheaper-version-wegovy-pill-prompting-novo-nordisk-threaten-legal)

---

### ğŸ‡ºğŸ‡¸ With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 11:16
- **é‡è¦æ€§**: â­â­

> The majority of Bristol Myers Squibb's $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/stagnating-sales-older-legacy-meds-bms-leans-new-growth-drivers-weather-storm)

---

### ğŸ‡ºğŸ‡¸ Astellas tops expectations as Vyloy sales surge outshines trial setback

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 10:31
- **é‡è¦æ€§**: â­â­

> Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/astellas-tops-expectations-vyloy-sales-surge-outshines-trial-setback)

---

### ğŸ‡ºğŸ‡¸ A cut above: Veradermics locks in $256M IPO and shares spike

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 09:43
- **é‡è¦æ€§**: â­â­

> In its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according to a Securities and Exchange Commission filing. Veradermics is trading under the symbol "MANE."

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/cut-above-hair-regrowth-biotech-veradermics-locks-oversubscribed-256m-ipo)

---

### ğŸ‡ºğŸ‡¸ Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:27
- **é‡è¦æ€§**: â­â­

> Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company's momentum is such that it still expects revenues to reach between $80 billion and $83 billion, which would be a 25% increase from 2025 sales at the midpoint.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026)

---

### ğŸ‡ºğŸ‡¸ AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&amp;J competition

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:08
- **é‡è¦æ€§**: â­â­

> AbbVie's immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company's yearly haul of $61.1 billion.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj)

---

### ğŸ‡ºğŸ‡¸ As CEO, Luke Miels wants GSK to be more 'product-centric'

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 09:10
- **é‡è¦æ€§**: â­â­

> In his first investor update as GSKâ€™s CEO, Luke Miels defined a core of his vision for the companyâ€™s next chapter: â€œWe need to be more product-centric as a company.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/ceo-luke-miels-wants-gsk-be-more-product-centric)

---

### ğŸ‡ºğŸ‡¸ Amgen resists FDA request to pull rare disease drug Tavneos from the market

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 07:41
- **é‡è¦æ€§**: â­â­

> Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said Tuesday as it presented quarterly financial results.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/amgen-resists-fda-request-pull-rare-disease-drug-tavneos-market-0)

---

### ğŸ‡ºğŸ‡¸ India will invest $1.1B to boost development of biologics, biosimilars

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 14:10
- **é‡è¦æ€§**: â­â­

> Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion) over the next five years to increase research and production of biologics and biosimilars

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/india-will-invest-11b-boost-development-biologics-biosimilars)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 14:25
- **é‡è¦æ€§**: â­â­

> Based on ads released in advance of the Super Bowl, little has changed in the eyes of the pharma industry since the FDA began a "crackdown" on drug marketing

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/05/fda-ftc-pbm-super-bowl-teva-autism-layoffs-vertex-amgen/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ The FDA wants to rein in drug ads. On Super Bowl Sunday, it will be business as usual

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 09:30
- **é‡è¦æ€§**: â­â­

> On Super Bowl Sunday, the drug industry is trotting out lounging football stars, a shouting DJ Khaled, and the soothing tones of Enya.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/drug-ads-super-bowl-sunday-fda/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about worries over FDA voucher program, a new U.S. Novo exec, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 14:09
- **é‡è¦æ€§**: â­â­

> FDA leaders tried to quell concerns about a controversial new program to fast-track certain drugs at an employee town hall meeting

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/04/novo-obesity-trump-psychedelics-fda-vouchers-switzerland/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:28
- **é‡è¦æ€§**: â­â­

> Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about obesity drug sales, Indiaâ€™s biopharma research push, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:30
- **é‡è¦æ€§**: â­â­

> The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/obesity-lilly-novo-sanofi-india-pfizer-fda/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 11:20
- **é‡è¦æ€§**: â­

> Bristol Myers Squibb has signed Kasey Keller for a Breyanzi partnership, giving the U.S, Soccer Hall of Famer a platform to discuss how the CD19-directed CAR-T cell therapy blocked the recurrence of his non-Hodgkin lymphoma.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bristol-myers-celebrates-us-soccer-legends-shutout-against-cancer-breyanzi-ad)

---

### ğŸ‡ºğŸ‡¸ OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 09:47
- **é‡è¦æ€§**: â­

> OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giantâ€™s CAR-T programs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/oxb-expands-bms-partnership-churn-out-lentiviral-vectors-car-t)

---

### ğŸ‡ºğŸ‡¸ TrumpRx, US government's cash-pay drug purchasing portal, primed for launch

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 14:31

> On Thursday evening, President Donald Trump is set to debut TrumpRx, a government-run website that will direct patients toward cash-pay channels where they can purchase certain prescription drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trumprx-governments-cash-pay-drug-purchasing-tool-primed-launch)

---

### ğŸ‡ºğŸ‡¸ Merz steps into the ring with Muhammad Ali-inspired Inbrija campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 07:41

> Merz Therapeutics has launched a punchy marketing campaign for Parkinsonâ€™s disease drug Inbrija, working Muhammad Ali quotes and footage into a revised version of the medâ€™s â€œFor the Fightersâ€ initiative.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/merz-steps-ring-muhammad-ali-inbrija-campaign)

---

### ğŸ‡ºğŸ‡¸ Sun Pharma marks Super Bowl â€˜SUNdayâ€™ with skin cancer awareness drive

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:53

> For Sun Pharma, every dayâ€”from Super Bowl Sunday and beyondâ€”is â€œSUNday.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/sun-pharma-marks-super-bowl-sunday-skin-cancer-awareness-drive)

---

### ğŸ‡ºğŸ‡¸ Novartis CEO projects 2026 growth despite â€˜largest patent expiryâ€™ in company history

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 13:40

> Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmakerâ€™s fourth-quarter results start to show the impact of the â€œlargest patent expiryâ€ in its history.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novartis-ceo-projects-2026-growth-despite-largest-patent-expiry-company-history)

---

### ğŸ‡ºğŸ‡¸ UPDATE: Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the door

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 13:39

> Novo Nordisk turned in sales and profit growth in 2025 amid an intense obesity market rivalry with Eli Lilly. But investor optimism came to a sudden halt Tuesday as the company warned of significant sales and earnings declines in 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novo-shares-plummet-sales-profit-warning-26)

---

### ğŸ‡ºğŸ‡¸ Sweden's Nanologica acquires API facility from CDMO Ardena, brings team of 45 on board

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 08:31

> Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardenaâ€™s Syntagon manufacturing facility in a stock deal valued at 8.6 million Swedish kroner ($961,000).

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/swedens-nanologica-acquires-ardenas-syntagon-facility-stock-trade-deal)

---

### ğŸ‡ºğŸ‡¸ A 'game of inches': Pfizer channels Al Pacino in World Cancer Day ad

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 12:22

> To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/pfizer-channels-al-pacino-spirited-world-cancer-day-ad)

---

### ğŸ‡ºğŸ‡¸ HHS launches $100M antiviral prize to develop broad-spectrum therapies

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 14:39

> While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/hhs-launches-100-million-antiviral-prize-develop-broad-spectrum-therapies)

---

### ğŸ‡ºğŸ‡¸ Charles River to close cell therapy CDMO site, lay off 20 staffers

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 12:02

> Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will cost the company 20 jobs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers)

---

### ğŸ‡ºğŸ‡¸ Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 11:43

> As top-selling Keytruda inches closer to its 2028 patent cliff, Merck's confidence in sustainable growth for the future is "as high as it's ever been," CEO Robert Davis said on the company's full-year 2025 earnings call.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers)

---

### ğŸ‡ºğŸ‡¸ Statins donâ€™t cause most of the side effects on package warnings, study finds

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 23:30

> Many people who should be taking statins avoid them for fear of side effects. A large new study says most of those side effects don't actually show up.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/statin-side-effects-evidence-lacking-lancet-study-says/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo Nordisk accuses Hims & Hers of â€˜illegal mass compoundingâ€™ over a cheaper version of Wegovy pill

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 20:51

> Hims &#38; Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of â€œillegal&#8230;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/05/novo-weight-obesity-wegovy-hims-compounding-telehealth/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ What to know about TrumpRx, the Trump administrationâ€™s prescription drug platform

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 18:00

> On Thursday, President Trump launched TrumpRx, the website he and his aides have touted for months as a platform aimed at lowering prescription drug prices.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/trumprx-what-to-know-drug-prices/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo and Lilly both see price cuts as helpful for long-term gain

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 14:36

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/biotech-news-novo-and-lilly-price-cuts-for-gain/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Opinion: TrumpRx has a fundamental flaw

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 09:30

> The real winners from TrumpRx are pharmaceutical manufacturers.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/trumprx-prescription-drug-costs-flaws/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Vertexâ€™s CRISPR treatment for sickle cell disease hits unexpected roadblock

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 09:30

> Vertex is running out of time to establish Casgevy as a transformative treatment for sickle cell.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/vertex-crispr-sickle-cell-treatment-casgevy-faces-rollout-bottleneck/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: FTC settles lawsuit with Express Scripts over charges it manipulated insulin prices, impeded access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 18:07

> The FTC settled a lawsuit against Express Scripts over allegations that the company artificially inflated the price of insulin and impeded access to treatment.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/04/pbm-cigna-express-scripts-ftc-insulin-settlement-rebates/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer defends data on Metsera candidate

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 14:44

> And other biotech news, brought to you by the Readout Newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/04/biotech-news-pfizer-defends-metsera-data/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 17:38

> Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer unveils data on Metsera drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:41

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer moves forward with its hopes for a monthly obesity drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 12:22

> Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing increasingly competitive.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/pfizer-obesity-weight-loss-drug-monthly-metsera-pf3944-met097/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: As U.S. officials move to reduce animal testing in research, focus may shift to restrictions on imports

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 09:30

> The Trump administration is seeking to reduce animal testing in research. Some activists are pushing the administration to suspend primate imports for research purposes entirely.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/03/animal-lab-research-imports-kennedy/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: A play takes on Novoâ€™s myth and money

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:51

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/biotech-news-golden-calf-novo-nordisk-play-theater/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 13:47

> Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/pfizer-sanofi-rsv-vaccine-uk/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimerâ€™s

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 09:30

> Why Bristol Myers Squibb is banking on a decades-old drug to help secure its future.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/?utm_campaign=rss)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ Oncology (Cancer)/Hematologic Malignancies Approval Notifications

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:46
- **é‡è¦æ€§**: â­â­â­â­

> FDA does not&nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&nbsp;Drugs@FDA&nbsp;for the latest approvals and prescribing information for specific products.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)

---

### ğŸ‡ºğŸ‡¸ List of Determinations Including Written Request

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:49
- **é‡è¦æ€§**: â­â­â­â­

> In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/list-determinations-including-written-request)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:46
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:44
- **é‡è¦æ€§**: â­â­

> The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers sho

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine)

---

### ğŸ‡ºğŸ‡¸ Cefiderocol Injection

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 17:07
- **é‡è¦æ€§**: â­â­

> Cefiderocol Injection - FDA Identified Interpretive Criteria

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/cefiderocol-injection)

---

### ğŸ‡ºğŸ‡¸ Notices of Updates

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 17:04
- **é‡è¦æ€§**: â­â­

> Webpage providing notices of updates to FDA's STIC webpages for antibacterial and antifungal drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/notices-updates)

---

### ğŸ‡ºğŸ‡¸ Newly Added Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:55
- **é‡è¦æ€§**: â­â­

> Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ Rare Disease Drug Approvals

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:38
- **é‡è¦æ€§**: â­â­

> This page describes recent rare disease drug approvals that received a CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals)

---

### ğŸ‡ºğŸ‡¸ Office of Infectious Diseases Research Activities

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:35
- **é‡è¦æ€§**: â­

> Overview of research needs, requests for information (RFIs), public workshops/meetings, opportunities for collaboration (this applies to RFI), notable guidances related to regulatory science, externally awarded research studies, and other important regulatory science and research activities.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-infectious-diseases-research-activities)

---

### ğŸ‡ºğŸ‡¸ Search for Regulatory References | Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 00:02

> Find information on drug development, applications, submissions, manufacturing &amp; quality, safety, labeling and more

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/search-regulatory-references-drugs)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 21:13

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ Recently Issued Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:30

> This page lists Recently Issued CBER and Cross-Center Guidance Documents.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ National Drug Code Directory

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 18:59

> National Drug Code Directory

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory)

---

### ğŸ‡ºğŸ‡¸ Electronic Registration and Listing Compliance Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 18:59

> Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-registration-and-listing-compliance-program)

---

### ğŸ‡ºğŸ‡¸ INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 18:28

> INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/news-events/expanded-access/informed-consent-template-individual-patient-expanded-access)

---

### ğŸ‡ºğŸ‡¸ Antibacterial Susceptibility Test Interpretive Criteria

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 17:02

> Antibacterial Susceptibility Test Interpretive Criteria

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria)

---

### ğŸ‡ºğŸ‡¸ E22 General Considerations for Patient Preference Studies

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:54

> E22 General Considerations for Patient Preference Studies

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/e22-general-considerations-patient-preference-studies)

---

### ğŸ‡ºğŸ‡¸ Rare Disease News, Events & Reports

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:38

> Learn more about recent news and events related to rare diseases and read ARC Program Annual Reports.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-news-events-reports)

---

### ğŸ‡ºğŸ‡¸ Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:38

> As part of the Accelerating Rare disease Cures (ARC) Program, CDERâ€™s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/learning-and-education-advance-and-empower-rare-disease-drug-developers-leader-3d)

---

### ğŸ‡ºğŸ‡¸ Rare Diseases Team

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:38

> The Rare Diseases Program facilitates, supports and accelerates the development of drug and biologic products for the benefit of patients with rare disorders

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-diseases-team)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:18
- **é‡è¦æ€§**: â­â­â­â­

> The US sees around 476,000 new Lyme cases every year

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/)

---

### ğŸ‡ºğŸ‡¸ Patient-centric oncology trials

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-05 11:35
- **é‡è¦æ€§**: â­â­

> Data-driven, patient-first: using insights in striving to transform cancer care

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/thought_leadership/patient-centric-oncology-trials/)

---

### ğŸ‡ºğŸ‡¸ IBSA UK&I launches Perovial for the treatment of acute Peyronieâ€™s disease

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:32
- **é‡è¦æ€§**: â­â­

> Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/)

---

### ğŸ‡ºğŸ‡¸ Connect more

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-05 11:42

> Redefining the future of customer relationships in biopharma

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/thought_leadership/connect-more/)

---

### ğŸ‡ºğŸ‡¸ Thomas Farrell

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-04 09:48

> NanoSyrinx has appointed Thomas Farrell as CEO and Director

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/thomas-farrell/)

---

### ğŸ‡ºğŸ‡¸ Ahmed Moussa

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-04 09:42

> Ahmed Moussa is the new Sanofi Country Lead for UK &#038; Ireland

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/ahmed-moussa/)

---

### ğŸ‡ºğŸ‡¸ Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:43

> The company will initially develop a vaccine to tackle colorectal and pancreatic cancers

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/)

---

### ğŸ‡ºğŸ‡¸ ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:08

> Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-02-06 04:14:16*